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CD10 constitutes a favourable prognostic marker for childhood acute lymphoblastic leukaemia. Since correlations between
CD10, cell cycle and apoptotic abilities were demonstrated in various cell types, we investigated whether differences existed in
the cycling/apoptotic abilities of CD10-positive and CD10-negative B acute lymphoblastic leukaemia cells. Twenty-eight cases
of childhood acute lymphoblastic leukaemia (mean age of 6.8 years) were subdivided into two groups according to high (17
cases, 93.2+4.5%, MRFI 211+82 CD10-positive cells) or low (11 cases, 11.5+6.2%, MRFI 10+7 CD10-negative cells)
expression of CD10. CD10-positive acute lymphoblastic leukaemia cells were cycling cells with elevated c-myc levels and
propensity to apoptosis, whereas CD10-negative acute lymphoblastic leukaemia cells had lower cycling capacities and c-myc
levels, and were resistant to apoptosis in vitro. A close correlation between all these properties was demonstrated by the
observations that the few CD10-positive cells found in the CD10-negative acute lymphoblastic leukaemia group displayed
elevated c-myc and cycling capacities and were apoptosis prone. Moreover, exposure of CD10-positive acute lymphoblastic
leukaemia B cells to a peptide nucleic acid anti-gene speciﬁc for the second exon of c-myc caused inhibition of c-myc
expression and reduced cell cycling and apoptotic abilities as well as decreased CD10 expression.
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Malignant B cells from the majority of childhood acute lympho-
blastic leukaemia (ALL) cases are characterised by the surface
expression of CD10, previously known as common acute lympho-
blastic leukaemia antigen or CALLA (as reviewed in LeBien and
McCormack, 1989; Shipp and Look, 1993; Weir and Borowitz,
2001). Although initially considered a tumour speciﬁc antigen,
CD10 was subsequently detected on a variety of normal cells of
haemopoietic and non haemopoietic origin. CD10, also called
neutral peptidase 24.11 or NEP, possesses a well-deﬁned enzymatic
activity, but its function in the physiology of lymphoid cells is
largely unknown. From the standpoint of childhood ALL, CD10
expression represents a favourable, although not independent,
prognostic marker (Pui et al, 1993; Consolini et al, 1998). The
reason as to why a surface molecule has impact on prognosis is
not known, although a number of observations on other cell types
suggest that CD10 may mark cells with special cycling and apopto-
tic abilities. For example, CD10 was found on the surface of cells
that are particularly prone to apoptosis such as normal germinal
centre B cells (Liu et al, 1992) or malignant cells from Burkitt’s
Lymphomas (BL) (Rowe et al, 1987). Moreover, it was observed
that CD10 was expressed by T cells induced into apoptosis by a
variety of means in vitro (Cutrona et al, 1999). Finally, c-myc upre-
gulation not only induces cell entry into the early phases of cell
cycle, but also renders the cells apoptosis-prone and concomitantly
induces CD10 expression (Cutrona et al, 1995, 2000).
Based on the above observations, we reasoned that expression of
CD10 by malignant B cells from ALL might indicate a special
cycling ability as well as a propensity to undergo apoptosis. Indeed,
in this study we demonstrate that expression of CD10 marks malig-
nant ALL cells that are apoptotis-prone and actively cycling and
express high levels of the c-myc oncogene. By contrast, CD10-nega-
tive ALL cells have lower c-myc levels and inferior cycling and
apoptotic properties under the same in vitro conditions. CD10-
positive ALL comprise different subgroups characterised by distinc-
tive cytogenetic abnormalities. Nevertheless all of these cells appear
to share the same cycling/apoptotic features, which can represent a
common prognostic factor.
MATERIALS AND METHODS
Patients
Bone marrow aspirates of 28 cases of childhoood pre-B ALL (mean
age of 6.8 years) were obtained from hospitals afﬁliated with the
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(AIEOP). Diagnosis of B ALL was based on morphological analysis
of bone marrow aspirates according to the French–American–
British (FAB) guidelines (Bennett et al, 1981), and on cytochemical
and phenotypic features of the leukaemia cells. Such features
include positive nuclear staining for terminal deoxynucleotidil
transferase, negative staining for myeloperoxidase, expression of
B-cell differentiation markers such as CD19 and cytoplasmic Ig m
chains and absence of surface Ig. Karyotype analysis did not reveal
any chromosomal abnormality in which the c-myc oncogene could
be involved, i.e. t(8; 14), t(2; 8), or t(8; 22) (Magrath, 1990). At the
time of study, ALL patients were at the onset of disease and were
untreated. All the bone marrow samples were stored in liquid
nitrogen (71808C) until tested. In the experiments with PNAs
(see below), freshly prepared cells from cases #655, 657, 659, 660
and 661 were employed.
Cytogenetic analysis
Bone marrow aspirates were processed as previously described
(Sainati et al, 1997). The cytogenetic studies were performed using
Trypsin–Giemsa banding technique. Chromosomes were identiﬁed
and assigned according to the International System for Human
Cytogenetic Nomenclature (Mitelman, 1995).
Detection of speciﬁc chromosome gene aberration by RT–
PCR
Total RNA was isolated by using the RNAzol-B reagent according
to the manufactory protocol (Duotech srl Milan, Italy). Two
micrograms of total RNA from each specimen was reversed tran-
scribed by using the Superscript reverse trascriptase (Life
Technologies Milan, Italy) and random examers: PCR ampliﬁcation
was performed using Amplitaq polymerase (Applied Byosistem)
according to BIOMED-1 (van-Dongen et al, 1999) protocols. A
screening for the following fusion gene transcripts t(1;19) with
E2A-PBX1, t(4;11) with MLL-AF4, t(9;22) with BCR-ABL p190
and BCR-ABL p210, t(12;21) with TEL-AML1, was performed.
An indipendent PCR reaction was performed with shift primers
for conﬁrmation of each positive result. The ABL housekeeping
gene expression was assessed to determine the presence of ampliﬁc-
able RNA and the efﬁcacy of reverse transcriptions. The
electrophoresed PCR reaction products were stained with ethidiun
bromide.
Cells and cell cultures
Mononuclear cell fractions were puriﬁed from bone marrow aspi-
rates by centrifugation on Ficoll-Hipaque gradients (Seromed,
Biochrom KG, Berlin, Germany). All of the suspensions were
comprised of more than 90% leukaemia cells except for cases
#738 and 702, in which there were 55 and 69% leukaemic cells,
respectively. Where indicated, special staining procedures had to
be employed for these cases.
The LAM C4 cell line, derived from a Burkitt lymphoma patient,
with the typical t(8; 14) translocation and c-myc over-expression
was used as a positive control in the studies on c-myc expression
(Roncella et al, 1993).
The culture medium used throughout was RPMI 1640
(Seromed) supplemented with 10% FCS (Seromed).
Flow-cytometry
The following mAbs were used for immunoﬂuorescence staining:
anti CD10 (J5) (Coulter Corp., Hielah, FL, USA), and anti CD19
(Leu-12) (Becton Dickinson & Co., Sunnyvale, CA, USA). Both
of these mAbs were used in indirect immunoﬂuorescence. The
secondary FITC- or PE-conjugated antibodies to the appropriate
murine Ig isotype were from Southern Biotechnology (Birming-
ham, AL, USA). Permeabilised cells were stained for indirect
immunoﬂuorescence with a murine anti Myc mAb (6E10 clone,
Cambridge Research Biochemicals, Cheshire, UK), an anti Ki67
mAb (DAKOPATTS, Glostrup, Denmark), and an anti Ig m chains
(Becton Dickinson & Co.) as previously reported (Cutrona et al,
1997). The samples were analysed by ﬂow cytometry (FACS Cali-
bur, Becton Dickinson & Co.). Data were expressed as
histograms of ﬂuorescence intensity vs cell number or as relative
ﬂuorescence intensity (MRFI) calculated according to the following
formula: mean ﬂuorescence intensity of cells stained with the mAb/
mean ﬂuorescence intensity of control cells treated with an unre-
lated mAb.
Two-colour analysis of 5-bromo-deoxyuridine (BrdUrd) (Sigma
Aldrich, Milan, Italy) incorporation and DNA content was
performed according to a modiﬁcation of the method of Dolbeare
et al (1985) as previously described (Dolbeare et al, 1985; Cutrona
et al, 1997).
CD10 positive and negative cells from CD10-negative ALL cases
were separated by cell sorting (FACS Calibur, Becton Dickinson &
Co.). The two populations were gated on the basis of CD10 expres-
sion and the forward light scatter parameter.
Measurements of ploidy (DNA index, DI) was carried out by
staining samples with a hypotonic solution of PI using an auto-
mated DNA staining device (DNA-prep reagents; Coulter) and
analysed by ﬂow cytometry (Epics XL; Coulter). DNA histograms
were obtained by a cell cycle analysis program (Multicycle; Phoe-
nix, San Diego, CA, USA). Leukaemic cells were classiﬁed as
diploid when the DI was between 0.9 and 1.09; as hyperdiploid
when the DI was 1.8 and less then 1.80; and as hypodiploid when
DI was 50.9. The DI was established from the ratio of the modal
channel number of the G0/G1 peak of neoplastic cells to that of
normal cells.
Western blot
Western blot analysis for MYC protein was performed as
previously described (Cutrona et al, 1995). The nitrocellulose
membranes were immunoblotted with an anti Myc hybridoma
supernatant (9E10 clone, kindly provided by Dr R Sitia, San
Raffaele Institute, Milan, Italy) or a rabbit antiserum to histone
2b (H2b) (kindly provided by Dr U Pfeffer, CBA, Genoa, Italy).
PCR methodologies
The PCR technique for analysis of V(D)J rearrangements and of
HCDR3 length was performed as previously described (Dono et
al, 1996). A RT–PCR methodology was used to detect c-myc
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) RNA
expression by the leukaemia cells treated in different manners
(Cutrona et al, 1997).
Apoptosis assays
Five610
5 per ml cells were cultured in RPMI medium (Seromed)
supplemented with 10% FCS (Seromed). The cultures were
harvested at different intervals and the apoptotic cells were detected
by using Annexin-V conjugated with FITC (Apolert
tm Apoptosis
Kit, Clontech Laboratories Inc., Palo Alto, CA, USA), by PI stain-
ing, or by DNA laddering, as previously described (Cutrona et al,
1999).
PNA anti-gene
A 17-mer anti myc PNA, complementary to a unique sequence
located at the beginning of the second exon of the c-myc oncogene
(TCA ACG TTA GCT TCA CC) was used. This PNA was modiﬁed
by addition of a Nuclear Localization Signal peptide (NLS) PNA-
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by a 3-base substitution (TTA ACG CTA GCT TTA CC), but
unchanged purine/pirimidine ratio (PNA-mycmut-NLS) was used
as control. The PNAs described were purchased from TIB
MOLBIOL (Berlin, Germany).
Statistical methods
Mean, standard deviation, and standard error were calculated for
each of the markers determined for the two groups of patients
investigated. Mean differences by groups of patients were evaluated
via the Student’s t-test and, when necessary (i.e., skewness and/or
heteroscedasticity in the biomarker distributions), statistical testing
was applied on long transformed variables (Armitage and Berry,
1987). All statistical comparisons and related P-values were two
tailed. Mean differences were considered signiﬁcant when P-values
were less than or equal to 0.05.
RESULTS
Deﬁnition of CD10-positve and CD10-negative ALL
The cells from the bone marrow of 28 ALLs of B cell origin
were simultaneously stained for CD10 and CD19. As shown in
Figure 1, the ALL cases were subdivided into two groups: one
(17 cases) with a high CD10 expression (480% CD19-expressing
cells were CD10 positive, MRFI 211+82), and one (11 cases)
with low CD10 (420% CD19-expressing cells were CD10 posi-
tive, MRFI 10+7). Both these differences were highly
signiﬁcant (P50.001 for both percentage positive cells and MRFI
values). Cases belonging to the ﬁrst group, i.e. high CD10
expression, were deﬁned as CD10-positive, while cases falling in
the second group, i.e. low CD10 expression, were considered as
CD10-negative.
Next, we investigated whether correlations existed in the differ-
ent cases between the presence of certain chromosome
abnormalities and CD10 expression. The 28 ALLs of B cell origin
were analysed for the fusion gene transcripts t(1;19) with E2A-
PBX1, t(4;11) with MLL-AF4, t(9;22) with BCR–ABL p190 and
BCR–ABL p210, t(12;21) with TEL-AML1 by RT–PCR. As
shown in Table 1 only one out of 14 CD10-positive and two
out of 10 CD10-negative ALL cases displayed the t(4;11) translo-
cation, three out of 14 CD10-positive ALL cases displayed t(12;21)
rearrangement and t(9;22) was negative in all of the cases
analysed. Notably, because of the study design, all of the cases
tested did not display any of the typical translocations of BL
(Magrath, 1990).
Differences in spontaneous apoptosis in vitro
Here, we investigated whether the malignant cells from CD10-posi-
tive ALL had higher spontaneous apoptotic capacities than those
from CD10-negative cases. Apoptosis was measured by PI staining
in cells taken ex vivo or after 24 h in culture. While the proportion
of apoptotic cells in the suspensions ex vivo was very low in the
two groups (mean 4+3.8) (Figure 2), signiﬁcant differences were
noted after culture. Apoptotic cells in the CD10-positive ALL
group were 66.7+9.1% vs 22.3+10.5% in the other group
(P50.001). These differences were further conﬁrmed by measuring
the DNA laddering (Figure 2).
Differences in cell cycle status
Next, we investigated the cell cycling abilities of CD10-positive
and CD10-negative ALL cells. Eight CD10-positive and seven
CD10-negative ALL cases were stained for Ki67, which is
expressed from the late G1 phase of the cell cycle (Gerdes et
al, 1984). The proportion of Ki67-expressing cells was signiﬁ-
cantly higher in the CD10-positive than in the CD10-negative
ALL cases (63.66+23% vs 27.37+9.4%, P=0.009, see Figure
3A). Figure 3A also shows typical ﬂow cytometry proﬁles where
a bimodal distribution of Ki67-positive cells is evident for each
group.
In another experiment, we investigated BrdUrd incorporation by
the CD10-positive and CD10-negative ALL following 1 h in
culture. The incorporation of BrdUrd was much higher in the
CD10-positive than in the CD10-negative ALLs (average
47.52+21.27% vs 7.66+7.84%, P=0.001) (Figure 3B). Figure 3B
also shows a typical ﬂow cytometry proﬁle obtained in a test where
the cells were pulsed with BrdUrd for 1 h, PI stained and analysed
by ﬂow cytometry. Most of the cells from the CD10-positive ALL
were in the G1-S phase, whereas the majority of the cells from
the CD10-negative ALL were in the G0-G1 phase of the cell cycle,
a ﬁnding which is in agreement with the results of the Ki67 stain-
ing.
The cells from ﬁve CD10-positive ALL cases (775, 743, 1022,
745 and 657) were pulsed with BrdUrd for different time intervals
before PI staining and ﬂow cytometry analysis. Most of the cells
were already in the S phase of the cell cycle after 1 h. At later
times, there were very few cells in the M phase, whereas the
majority of the cells underwent apoptosis from the G1-S phase
of the cell cycle, as shown by the ﬁnding that virtually all of
the hypodiploid cells seen at 48 h had also incorporated BrdUrd
(Figure 3C).
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Figure 1 Deﬁnition of CD10-positive and CD10-negative ALL. Bone
marrow cell suspensions were stained for CD19 and CD10. CD19-positive
cells were gated and the percentage of CD10-positive (top scale) cells or
the MFRI for CD10 (bottom scale) were recorded. Two typical ﬂow cyto-
metry proﬁles for CD10 are also shown.
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Cell undergoing apoptosis from the G1-S phase of the cell cycle
often overexpress c-myc (Hueber and Evan, 1998). To explore
this issue further, CD10-positive and CD10-negative ALL were
analysed for the expression of Myc protein by immunoﬂuores-
cence. Single staining was carried out in all cases in which
there were greater than 80% neoplastic cells (i.e., CD19
+/
CD10
+ or CD19
+/CD10
- large blasts), while in two cases, where
the proportion of malignant cells was lower (#738 and 702),
double staining for surface CD19 and intracytoplasmic Myc
was carried out. The data, summarised in Figure 4A, show a
signiﬁcant difference in Myc expression. CD10 positive ALL cases
had an average MRFI of 69.24+25.3 vs 14.98+6 of CD10-nega-
tive ALL cases (P50.001). These ﬁndings were conﬁrmed by
Western blot analysis (Figure 4B). The percentages of cells posi-
tive for Myc were not determined since the cells of both groups
displayed some positive ﬂuorescence, as indicated by the typical
proﬁles shown in the inset of Figure 4A. It could be argued that
because of its relatively short half life (Hann and Eisenman,
1984), Myc expression was inﬂuenced by the cryopreservation
of the cells. However, extensive comparative tests carried out
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Table 1 Cytogenetic analysis of CD10-positive and CD10-negative B-ALL
Patient CD10 %
a Cariotype
b Ploidy
c t(12;21) t(4;11) t(1;19) t(9;22) p190 t(9;22) p210
745 95.9 46, XY diploid +
d 7
d 77 7
738 55.1 46, XY hyperdiploid + 77 7 7
743 93.6 nd
e diploid 77 7 7 7
775 94.1 nd nd nd nd nd nd nd
702 69.1 46, XY nd 77 7 7 7
1022 96.6 nd diploid 77 7 7 7
1422 92.6 46, XY, der 3, der 12 diploid + 77 7 7
996 87 nd hyperdiploid 77 7 7 7
1307 86.8 45, XX, (10%)45, XX, del(9)(p21), 720(90%) diploid 77 7 7 7
1059 98.3 nd nd 77 7 7 7
1348 90.3 46XX, (15%)/47, XXY, t(4;11)(q21;q23)(85%) hyperdiploid 7 + 77 7
1089 93.4 45, XX, 720 hypodiploid 77 7 7 7
655 82 nd nd nd nd nd nd nd
657 95 46, XY hyperdiploid 77 7 7 7
659 98 nd nd nd nd nd nd nd
660 93 46, XX diploid 77 7 7 7
661 93.9 nd hyperdiploid 77 7 7 7
282 1 46, XX, t(4;11)(q21;q23) diploid 7 + 77 7
748 4 46, XX, t(4;11)(q21;q23) diploid 7 + 77 7
441 7.9 46XX, 9p7/48, XX, 9p7, +8, +12 nd nd nd nd nd nd
843 15.7 46, XY diploid 77 7 7 7
571 16.2 46, XY diploid 77 7 7 7
1110 5.6 46, XY hypodiploid 77 7 7 7
1384 10 47, XX, +21 nd 77 7 7 7
470 18.5 nd nd 77 7 7 7
621 12.3 nd nd 77 7 7 7
1372 17.8 46, XX diploid 77 7 7 7
570 17.8 46, XY diploid 77 7 7 7
aPercentage of CD10 positive leukaemic cells was determined by immunoﬂuorescence and ﬂow cytometry analysis;
bCariotype analysis was assessed by Trypsin-Giemsa banding
technique;
3Ploidy was deﬁned based upon DI values (see Materials and methods);
d+ and 7 indicate presence or absence of fused gene transcripts by PCR analysis, respectively;
end=not determined.
100
80
60
40
20
0
%
 
A
p
o
p
t
o
s
i
s
0 h
24 h
7
4
5
7
3
8
7
4
3
7
7
5
7
0
2
1
0
2
2
1
4
2
2
9
6
6
1
0
8
9
6
5
5
6
5
7
6
5
9
6
6
0
6
6
1
Pt. #
CD10+ ALL CD10– ALL
2
8
2
7
4
8
4
4
1
8
4
3
5
7
1
1
1
1
0
4
7
0
6
2
1 CD10+
ALL
CD10–
ALL
0
 
h
2
4
 
h
0
 
h
2
4
 
h
Figure 2 Apoptotic capacities of CD10-positive and CD10-negative ALL cells. Cells from the indicated cases were tested for apoptosis by PI staining
either immediately after isolation or following 24 h in culture (left). Apoptotic capacities were conﬁrmed by measuring DNA laddering (two typical experi-
ments are shown on the right).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(11), 1776–1785in case 657 demonstrated that cryopreservation did not affect
Myc expression. Moreover, cases (655, 657, 659, 660, 661) were
also tested using freshly drawn cells.
Features of CD10-positive cells isolated from CD10-
negative ALL cases
Next, we investigated the characteristics of the few CD10-positive
cells detected in the CD10-negative ALL cases. The cells from six
cases (571, 1372, 621, 1384, 470 and 843) were stained with
CD10 mAb and the CD10-positive cells were FACS-sorted. Sufﬁ-
cient quantities of CD10-positive and CD10-negative cells could
be isolated for further analyses. As shown in Figure 5 (which
reports one representative experiment on cells from patient
#571), CD10-positive cells were actively cycling, with high levels
of c-myc and a special propensity to undergo apoptosis in vitro,
whereas CD10-negative cells had low c-myc levels and low cycling
and apoptotic capacities (Figure 5). These data demonstrate a
different functional status in two cell populations that originated
from the same clone, as shown by the analyses of their V(D)J rear-
rangements (see Figure 5).
Role of c-myc in apoptosis, cell cycle and CD10 expression
Here, we tested the hypothesis that the high level of c-myc
conferred to CD10-positive ALL cells both a superior cycling
capacity and a more pronounced propensity to undergo apopto-
sis. To this end, c-myc expression was blocked using a PNA anti
c-myc anti-gene. PNAs are synthetic structural homologues of
nucleic acids in which the phosphate-sugar polynucleotide back-
bone is replaced by a ﬂexible polyamide (Egholm et al, 1992).
They can bind to the complementary DNA sequences more
stably than DNA itself (Egholm et al, 1993). However, to be
effective on intact cells in vitro, PNAs must be coupled to a
vector, which allows their transport to the cell nuclei (Nielsen,
1999). In this study, we used PNA with complementarity to a
sequence of the second exon of the c-myc oncogene. When
coupled to an appropriate nuclear localisation sequence (NLS),
this PNA-mycwt-NLS is able to penetrate cell nuclei and to selec-
tively block the expression of c-myc (Cutrona et al, 2000). A
PNA that differed for the presence of three mutations in the
sequence complementary to the c-myc sequence was used as
control (PNA-mycmut-NLS).
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Figure 3 Cell cycle status of CD10-positive and CD10-negative ALL. (A and B) Cells from the indicated cases were stained for Ki67 (A) or BrdUrd (1 h
pulse) (B) and analysed by ﬂow cytometry. Typical proﬁles of CD10-positive or CD10-negative ALL cases are shown at the bottom of each ﬁgure. (C) Cells
from a CD10-positive ALL were pulsed with BrdUrd for the indicated times, stained for PI and analysed by ﬂow cytometry. Apoptotic (hypodiploid cells) are
observed in the gates at the bottom of the ﬁgures.
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British Journal of Cancer (2002) 86(11), 1776–1785 ã 2002 Cancer Research UKCells from CD10-positive ALL were incubated with medium,
10 mM PNA-mycwt-NLS, or PNA-mycmut-NLS for 24 h. The
cultured cells were harvested and checked for c-myc expression
by ﬂow cytometry (Figure 6A), RT–PCR (Figure 6B) and Western
blot (Figure 6C). As shown in Figure 6, a mean reduction in MRFI
of 54+18% was noticed by immunoﬂuorescence and ﬂow cytome-
try. This reduction in c-myc expression was conﬁrmed by the two
other methods. Inhibition of c-myc expression was accompanied by
a signiﬁcant decrease of BrdUrd incorporation by the cells (Figure
6D), indicating a substantial decline in their cycling abilities.
In another series of experiments, freshly prepared cells were
incubated with PNA-mycwt-NLS, PNA-mycmut-NLS or medium
for 24 h. Subsequently, apoptosis was measured by PI or Annex-
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tosis (mean reduction 49.4+16.8%) was noticed in all of the ﬁve
cases tested. Figure 7A shows all of the data obtained by PI stain-
ing, which was indicative of both methods used (Figure 7B).
Finally, we checked whether a block in c-myc expression caused
a concomitant reduction in CD10-expression. As shown in Figure
8, in the four cases that were investigated, there was a substantial
inhibition (mean reduction 48+4.3%) of CD10 expression as
assessed by ﬂow cytometry (Figure 8).
DISCUSSION
This study demonstrates that malignant B cells of CD10-positive
ALL are mostly actively cycling, and are apoptosis-prone, whereas
the cells of CD10-negative ALL are not actively cycling, and do
not undergo apoptosis readily in vitro. In addition, the present data
show a close correlation between Myc levels and the cycling and
apoptotic capacities of the cells. Finally, these studies indicate that
CD10 expression distinguishes cells with different properties.
Various results from this study point to correlations between
CD10 expression and the cells’ biological behaviour in vitro. The
few CD10-positive malignant cells, present in those cases classiﬁed
as CD10-negative ALL, shared all of the characteristics of the
malignant cells found in the CD10-positive ALL cases, including
elevated c-myc levels and the propensity to undergo spontaneous
apoptosis. Furthermore, the block imposed on c-myc expression
by PNA mycwt-NLS was followed by inhibition of cell cycling, as
well as of the apoptotic capacities of the ALL cells. Upon c-myc
inhibition, there was also a substantial reduction of CD10 expres-
sion, thus conﬁrming the value of CD10 as a marker for cycling
and/or apoptosing ALL cells.
A wide range of results for Ki67 staining and BrUrd incorpora-
tion in ALL cases was reported in previous studies, but these
features were not correlated with the immunophenotype of the
malignant cells (Tsurusawa et al, 1995; Salomons et al, 1999).
Admittedly, most of the cases reported could have been CD10-
positve. This raises the questions as only in those cases the prolif-
erative capacities of the leukaemic cells were in general lower than
those observed for CD10-positive ALL cases in the present study.
Although there are no apparent explanations for these differences,
one should, however, point out that the ﬂow cytometry method
used here may have increased the ability of the techniques to detect
cycling cells.
The present study indicates a fundamental role of c-myc in the
apoptosis of ALL cells, since spontaneous cell death occurred in
vitro only in those cells that displayed elevated c-myc levels.
Whether this correlation holds true also for other types of apopto-
sis (e.g. drug or radiation induced) has to be further investigated,
although studies on different cell types overexpressing c-myc would
predict this to be the case (Rowe et al, 1987; Cutrona et al, 1995,
1997, 1999; de-Saint-Vis et al, 1995; Martinez-Valdez et al, 1996;
Mueller et al, 1997; Guedez et al, 1998a,b). A close correlation
between c-myc expression and apoptosis was ﬁrst indicated by
studies on murine ﬁbroblasts transfected with the c-myc oncogene
(Evan et al, 1992). Recent studies on cells induced to overexpress c-
myc in vitro have demonstrated that these cells have difﬁculties in
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late G1 phase or remain arrested in the G2 phase. These arrested
cells have a tendency to become aneuploid (often hyperdiploid)
(Felsher et al, 2000). The latter mechanism observed in vitro may
suggest an appealing model to explain the frequent hyperdiploidy
seen in CD10-positive ALL cells. In this respect, it is of note that
hyperdiploidy was detected in 41.7% of the CD10-positive ALL
cases studied (ﬁve out of 12, Table 1) (see also reviews Look,
1997; Faderl et al, 1998; Ito et al, 1999).
The ﬁnding of elevated c-myc levels raises questions regarding
the mechanisms involved in c-myc overexpression in CD10-positive
ALL cells. Chromosomal translocations typical of BL and L3
leukaemias, which juxtapose c-myc to the Ig gene loci and cause
c-myc overexpression, were excluded in all of the ALL cases selected
for this study. Therefore, other options have to be considered. One
possibility is that, because of the neoplastic transformation, the
CD10-positive ALL cells were frozen at a maturational stage char-
acterised by a physiological c-myc elevation and active cycling
capacities. Studies on murine B cells have demonstrated that under
particular circumstances, pre-B cells may proliferate autonomously
in vitro (Rolink et al, 2000) and conceivably also in vivo (Carsetti,
2000). Moreover, there is evidence in man that most CD10-positive
pre-B cells are actively cycling in vivo (Ghia et al, 1996). Another
plausible, and not mutually exclusive, option is that alterations
of oncogenes other than c-myc could be responsible for the malig-
nant transformation and for the upregulation of c-myc (and cell
proliferation). Finally, it is possible that in ALL cells the c-myc gene
presented a number of mutations which prolong the intracellular
half-life of its product, similar to that reported in certain BL cells
(Bahram et al, 2000; Fais et al, 2000). Central to this issue is the
problem of whether ALL cells express physiological (i.e. similar
to those seen in proliferating cells) or pathological (i.e. similar to
levels of those of BL) c-myc. Deﬁnitive proof for one or other
hypothesis awaits further studies.
Previous investigations on cells with elevated c-myc levels have
indicated that the choice between apoptosis or cell proliferation
is often dictated by the presence of additional signals capable of
promoting or preventing apoptosis (Bissonnette et al, 1992; Fanidi
et al, 1992). For example, B cells in which the c-myc oncogene has
been transfected and hyper-expressed would die in low serum
concentrations in vitro unless exposed to CD40L or to an agonistic
CD40 mAb which are both capable of inducing the upregulation of
bcl2 and possibly of other anti-apoptotic genes (Cutrona et al,
1995). These observations suggest that a number of signals, deliv-
ered either by contact with stromal cells or by cytokines, prevent
the apoptosis of CD10-positive ALL cells in vivo and facilitate their
proliferation (Welch et al, 1990; Manabe et al, 1992, 1994; Saeland
et al, 1992; Campana et al, 1994; Murti et al, 1996; Nishigaki et al,
1997). In this regard, it is of note that previous studies demon-
strated that the ability of ALL cells to survive when cultured on
stromal cells was an accurate predictor of a negative clinical
outcome irrespective of the cell proliferative ability in vitro, possi-
bly underlying the value of the anti-apoptotic properties of the
stromal cells in the survival/expansion of the malignant ALL cells
(Campana et al, 1993; Coustan-Smith et al, 1996; Kumagai et al,
1996).
Both CD10-positive and CD10-negative ALL are comprised of a
heterogeneous group of diseases characterised by different cytoge-
netic abnormalities. Although data on such abnormalities are not
available for all of the cases studied here, observations on a propor-
tion of the CD10-positive ALL points to their heterogeneity. Thus,
the t(4;11) translocation, which involves MLL-AF4 gene (Pui et al,
1991), was found in only one out of 14 CD10-positive and 2/10
CD10-negative ALL cases. Likewise t(12;21) causing TEL-AML1
(Romana et al, 1995; McLean et al, 1996; Borkhardt et al, 1997)
rearrangement was seen in three out of 14 CD10-positive ALL
cases.
The latter ﬁndings perhaps suggest a marginal involvement of
these translocations in the control of c-myc expression. On the
other hand, the intrinsic properties of the cells from the CD10-
negative ALL do not prevent them from expressing CD10 as shown
by the data in Figure 5, which reinforced the concept that CD10
expression is linked to the cycling/apoptotic properties. This
consideration may in part explain why CD10 expression represents
a non-independent prognostic marker of ALL. Thus, the superior
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Figure 8 Inhibition of CD10 expression by PNA-mycmut-NLS. Cells
from the indicated CD10-positive ALL cases were treated with PNAs or
medium alone for 24 h in culture and subsequently stained for CD10.
Fluorescence was measured by ﬂow-cytometry and expressed as MFRI.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(11), 1776–1785cycling and apoptotic features of CD10-positive ALL cells may
render them more susceptible to the external signals including
chemotherapeutic agents. However, additional features indepen-
dent of the cycling/apoptotic capacities of the cells may also
greatly inﬂuence the course of the disease.
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